Institut Pasteur Korea's AI Drug Development Lab optimizes selected active compounds through phenomic HTS/HCS system to derive leads and preclinical candidates. In the drug discovery process, the optimization process of a compound is a multidisciplinary research process that involves the optimization of the biological function and pharmaceutical properties of the drug. Accordingly, Institut Pasteur Korea's drug development research is accelerating the development of new drug candidates by incorporating cell-based drug efficacy analysis and structure based drug design into the process of optimizing compounds, predicting drug chemical properties, pharmacokinetic analysis, and toxicity studies using AI chemical bioinformatics. The AI Drug Development Lab is strategically conducting research on the development of therapeutic candidates by combining small molecule compound therapeutics design, medicinal chemistry research through synthesis, and artificial intelligence methodologies.

Recently, we have been selected for the K-MELLODDY national project and will continue to contribute to the acceleration and innovation of new drug development by serving as a bridgehead for AI drug development.

Our areas of activity include:
• Advancing and accelerating the optimization on drug discovery program by integrating medicinal chemistry with AI technology
• Developing novel chemical platform technology for innovative drug discovery (Establishment of PROTAC platform)
• Developing probe molecules for identifying target and understanding the in vivo mechanism of drug candidates
• Developing tool compounds for monitoring drug localization in either the cell or living animal
• Provide open analytical chemistry services, synthesis know-hows and molecular modeling analysis by giving access to IPK’s well-equipped infrastructure to support academia and pharmaceutical companies.